AGL can specifically bind to monoamine oxidase b and HO-1, which helps to inhibit Fe 2+ accumulation and ROS production, thereby maintaining mitochondrial function and preventing ferroptosis
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
Are there any side effects to taking glutathione
The serum is gentle, affordable and gives all-round impressive results
Here is the legal framework, quality control gap, and PCAC July 2026 update
What purity is LiveWell IGF-1 LR3, and is there a COA